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A B S T R A C T
Meta-analyses of retrospective and case-control studies support an association be-
tween a patent foramen ovale (PFO) and “cryptogenic stroke” (stroke without an iden-
tifiable cause), especially in young patients (age <55 years). Several reports have also 
suggested an increased risk of recurrent strokes in patients with PFO. Comparison of 
the two main strategies to reduce the risk of recurrent stroke in patients with cryp-
togenic stroke and PFO, antithrombotic therapy vs transcatheter closure of the PFO 
with a device, has shown PFO closure to confer a lower risk in non-randomized stud-
ies, which though has not been confirmed in randomized trials, although a tendency 
for a lower risk has been indicated, particularly in on-treatment or per-protocol analy-
ses (compared with the intention-to-treat analysis), and appears to be device specific. 
Thus, PFO closure cannot be presented as the recommended treatment, but it may be 
offered as an alternative option in select patients, e.g. those with large shunts or with 
atrial septal aneurysms.
I N T R O D U C T I O N
Patent foramen ovale (PFO) is a persistent fetal communication between the 
right and left atrium due to incomplete closure of the atrial septum. PFO is common 
in the general population. In many autopsy-based studies it shows a prevalence of 
approximately 27%.1 In most people the interatrial communication seals completely 
after birth. In around a quarter of the population, however, incomplete closure of the 
foramen results in a PFO that could provide a potential route for blood borne material 
from the venous to the systemic circulation (paradoxical embolism). Case reports of 
thrombus straddling a PFO (Fig. 1) confirm that material from the venous circulation 
can pass through the interatrial communication and cause systemic embolism to the 
brain and other organs,2 but the frequency and clinical relevance of this phenomenon 
are controversial. Case-control studies to assess whether PFO is more common in 
people with stroke are confounded by selection bias and have provided conflicting 
results. However, meta-analyses of these studies support an association between a 
PFO and stroke without an identifiable cause (“cryptogenic stroke”), especially in 
young patients (age <55 years).3,4 There are limited prospective data on the risk of 
stroke in otherwise healthy people with PFO. In one population-based study,5 the 
incidence rate of ischemic stroke was 1.22 and 0.89 per 100 person years in subjects 
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with and without PFO respectively, but this difference did not 
reach statistical significance. Several reports have also studied 
the risk of recurrent strokes in patients with PFO. The results 
of these studies are heterogeneous, but in a meta-analysis 
the pooled rate of recurrent stroke for patients on medical 
treatment was 1.6 events per 100 person years.6 Some studies 
also suggest that the risk of stroke is influenced by PFO size, 
the presence of an atrial septal aneurysm, or risk factors for 
thromboembolism, but the predictive value of these markers 
has not been confirmed.7,8 
in cryptogenic stroke study (PICSS), on the other hand, evalu-
ated acute stroke patients with and without PFO assigned to 
acetylsalicylic acid (325 mg daily) or warfarin,12 There was no 
significant difference with respect to two-year risk of recur-
rent stroke or death between the groups, or for patients with 
co-existing atrial septal aneurysm. A systematic literature 
review of 20 studies to examine the efficacy of transcatheter 
closure compared to antithrombotic therapy showed that the 
annual risk of recurrent transient ischemic attack (TIA) or 
stroke was lower in the group with closure than in patients who 
received antithrombotic therapy.13 This applied in particular 
to patients with co-existing atrial septal aneurysm. Many cli-
nicians therefore consider that closure is justified in patients 
with cryptogenic stroke and PFO to prevent stroke recurrence, 
but these non-randomized data may be confounded by imbal-
ances in the underlying risk of recurrent events between the 
two treatment groups. Moreover, PFO closure is associated 
with procedural and long term risks, and randomized clinical 
trials14 are required to fully evaluate the balance of risks and 
benefits of closure versus medical treatment.
R A N D O M I Z E D  S T U D I E S  A N D  M E E T A -
A N A l y S E S
To date, three randomized controlled trials of PFO clo-
sure with antiplatelet therapy versus medical therapy alone 
have reported results. The CLOSURE-I trial randomized 909 
patients with PFO and cryptogenic stroke or TIA to closure 
with the Starflex device combined with medical therapy (as-
pirin) versus medical therapy (aspirin or warfarin, or both). 
Successful implantation of a device was achieved in 81% of 
patients in the closure arm. At two years’ follow-up there was 
no significant difference in the rate of the primary endpoint 
(stroke, TIA, or death) between the 2 treatment groups (5.5% 
FIgURE 2. An Amplatzer PFO occluder visualized by 3D 
transesophageal ultrasound.
FIgURE 1. Thrombus straddling a PFO “caught in action”.
M A N A g E M E N T  O F  P A T I E N T S  W I T H  P F O 
A N D  C R y P T O g E N I C  S T R O K E
There are 2 main strategies to reduce the risk of recurrent 
stroke in patients with cryptogenic stroke and PFO: medical 
management which includes antiplatelet therapy and antico-
agulation, and transcatheter closure of the PFO with a device 
(Fig 2). 
The efficacy of acetylsalicylic acid was suggested by a multi-
center trial, which found that the incidence of recurrent stroke 
after 4 years of follow-up of 216 patients with cryptogenic 
stroke and PFO was greater than in stroke patients without 
an intracardiac shunt.9 Both groups were given acetylsalicylic 
acid (300 mg daily) as secondary prophylaxis. The incidence 
of recurrent stroke during the same period was four times as 
high in 51 of the patients with co-existing atrial septal aneu-
rysm. The conclusion of the study was that warfarin should be 
considered for this subgroup. 
Percutaneous closure has been used widely to prevent 
episodes of embolism through the interatrial communication, 
and observational studies suggest that this procedure lowers 
the risk of recurrent cerebrovascular events in patients with 
PFO when compared with medical management.10,11 The PFO 
PFO CLOSuRE
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in the closure group versus 6.8% in the medical therapy group). 
In most cases the recurrent neurological events were attributed 
to causes unrelated to the PFO, but left atrial thrombus was 
detected in four (1.1%) of the 366 closure patients who un-
derwent transesophageal echocardiography within 6 months of 
the procedure, two of whom had a stroke. Moreover, protocol-
defined major vascular complications occurred in 3.2% of the 
closure group but none of the medical therapy group, and atrial 
fibrillation was significantly more common in the closure group 
than in the medical therapy group (5.7% vs 0.7%).15
The PC trial randomized 414 patients with PFO and 
ischemic stroke, TIA, or extracranial thromboembolism to 
closure using the Amplatzer PFO occluder (St Jude Medical) 
or to standard medical care (antiplatelet therapy or antico-
agulation). A device was successfully implanted in 93.6% of 
the closure group. At a mean follow-up of around 4 years, 
the primary composite endpoint (death, non-fatal stroke, 
TIA, and peripheral embolism) had occurred in 3.4% of the 
closure group and 5.2% of the medical care group. As with 
CLOSuRE-I, there was a slightly higher rate of atrial fibril-
lation of new onset in the closure group (2.9% vs 1.0%), but 
there was no evidence of thrombus associated with the device.16
The recently published RESPECT trial randomized 980 
patients with PFO and cryptogenic stroke to closure with the 
Amplatzer PFO occluder (St Jude Medical) or to medical 
therapy alone (with anticoagulation or antiplatelet therapy).17 
The device was successfully implanted in 92.6% of the closure 
group. Over a mean 2.6 years of follow-up, the primary end-
point (recurrent fatal or non-fatal ischemic stroke or early 
death) occurred in 1.8% of the closure group and 3.3% of the 
medical therapy group. The investigators reported different 
durations of follow-up in the two arms of the trial because 
some patients in the medical arm withdrew from the study and 
underwent non-assigned PFO closure. Exploratory survival 
analyses by treatment received suggested that PFO closure 
might have reduced the risk of recurrent stroke. The rate of 
serious adverse events did not differ between the two groups, 
although the closure group showed slightly higher rate of new 
atrial fibrillation (3.0% vs 1.5%) and pulmonary embolism 
(1.2% vs 0.2%).17 
The results of the RESPECT trial indicate that PFO 
closure with the Amplatzer PFO Occluder is not superior to 
medical management in reducing recurrent strokes in patients 
with cryptogenic stroke and evidence of a PFO. There were, 
however, trends toward benefit on per-protocol analysis and 
in patients with large shunts and those with atrial septal an-
eurysms. In general, the overall negative results are consistent 
with those noted in the CLOSuRE I trial (with the STARFlex 
device) and the PC trial (also with the Amplatzer device). 
These data are hypothesis-generating, but do not support rou-
tine PFO closure in patients with cryptogenic stroke and PFO. 
It is possible that there might be a benefit in select subgroups. 
Overall, these 3 randomized trials enrolled 2303 partici-
pants over 5 to 9 years, but it is likely that a much larger number 
of patients underwent PFO closure at the 162 participating 
sites during the recruitment period,18 and it is unclear how 
the trial results relate to the wider population of patients 
with cryptogenic stroke and PFO. The individual trials have 
relatively small sample sizes and short follow-up times, and the 
hazard ratios are bounded by wide confidence intervals that 
encompass clinically relevant treatment effects. Furthermore, 
interpretation of the trial results is complicated by treatment 
crossovers and incomplete follow-up. 
Several meta-analyses of these 3 randomized trials (CLO-
SuRE I, PC, and RESPECT trials) have been performed.19-25 
The analyzed data concern 2,303 patients, of whom 1,150 were 
in the PFO closure group and 1,153 in the medical therapy 
group. In the intention-to-treat analysis, transcatheter device 
closure of PFO was not superior to standard medical therapy 
in the secondary prevention of cryptogenic stroke, but there 
was a trend in favor of the PFO closure, but also a trend for 
the more frequent occurrence of atrial fibrillation in the PFO 
closure group. In the as-treated or per-protocol analyses, the 
stroke and/or TIA risk was significantly less frequent in the 
PFO closure group. The conclusion has been that success-
ful transcatheter closure of PFO might be more effective 
than medical therapy alone for the prevention of recurrent 
thromboembolic events. Subjects with a substantial PFO shunt 
tended to benefit the most with transcatheter PFO closure 
(HR=0.35, P=0.06).24 
Recently, a pooled analysis was performed of the PC and 
RESPECT trials, in which a similar device was used, indicat-
ing beneficial effects of device closure: the effect-estimate 
hazard ratios being 0.54 (95% confidence intervals-CI: 0.29 
to 1.01) in the intention-to-treat, 0.48 (95% CI: 0.24 to 0.94) 
in the per-protocol, and 0.42 (95% CI: 0.21 to 0.84) in the as-
treated populations.25 
Also recently, a randomized trial, comparing 3 different 
devices (Amplatzer, CardioSEAL-STARflex, and Helex oc-
cluder, n=220 per group) for percutaneous closure of a PFO 
in 660 patients with cryptogenic stroke, showed significant 
differences in the neurological event rate among devices.26 
The authors concluded that procedural complications and 
long-term neurological event rates are low regardless of de-
vice used; however, the recurrent neurological event rate was 
significantly lower after the Amplatzer device implantation.26 
Finally, further results from ongoing randomized trials, includ-
ing REDuCE and CLOSE, are awaited in the near future. 
C O N C l U S I O N
In conclusion, based on current evidence, closure should 
not be presented as the recommended treatment, but it should 
be mentioned as an alternative option in selected patients 
(those with large shunts or with atrial septal aneurysms). 
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The patient then has the choice between a relatively simple 
and short procedure and life-long anticoagulants with their 
inherent risk over time. In older patients the risk of recurrent 
stroke attributable to PFO is likely to be small relative to the 
overall risk of stroke, especially in those with hypertension or 
other vascular risk factors. In most patients, a definite relation 
between the PFO and the index stroke cannot be established, 
and, regardless of whether device closure is recommended, 
other secondary prevention treatments, including antiplate-
let therapy, blood pressure control and cholesterol lowering 
agents will also be appropriate.
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